CN103372010B - Chukrasone B在制备治疗急性痛风药物中的应用 - Google Patents
Chukrasone B在制备治疗急性痛风药物中的应用 Download PDFInfo
- Publication number
- CN103372010B CN103372010B CN201310280853.0A CN201310280853A CN103372010B CN 103372010 B CN103372010 B CN 103372010B CN 201310280853 A CN201310280853 A CN 201310280853A CN 103372010 B CN103372010 B CN 103372010B
- Authority
- CN
- China
- Prior art keywords
- chukrasone
- acute gout
- preparation treatment
- treatment acute
- msu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 40
- 230000001154 acute effect Effects 0.000 title claims abstract description 32
- 229930187319 chukrasone Natural products 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract description 14
- 230000006378 damage Effects 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 6
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003511 endothelial effect Effects 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 3
- 229940116269 uric acid Drugs 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003448 neutrophilic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 244000309466 calf Species 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 102000006628 Kv1.2 Potassium Channel Human genes 0.000 description 3
- 108010087141 Kv1.2 Potassium Channel Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241001156380 Chukrasia tabularis Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310280853.0A CN103372010B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗急性痛风药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310280853.0A CN103372010B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗急性痛风药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103372010A CN103372010A (zh) | 2013-10-30 |
CN103372010B true CN103372010B (zh) | 2015-09-16 |
Family
ID=49458260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310280853.0A Expired - Fee Related CN103372010B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备治疗急性痛风药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103372010B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103655551B (zh) * | 2013-12-02 | 2015-04-22 | 黑龙江中医药大学 | Manzamenone O在制备治疗急性痛风药物中的应用 |
-
2013
- 2013-07-04 CN CN201310280853.0A patent/CN103372010B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Liu,H.B.et al..Chukrasones A and B:Potential Kv1.2Potassium Channel Blockers with New Skeletons from Chukrasia tabularis.《Organic Letters》.2012,第14卷(第17期),第4438–4441页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103372010A (zh) | 2013-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104107179A (zh) | 闭花木酮Cleistanone的二乙胺衍生物在制备抗急性痛风药物中的应用 | |
CN103372010B (zh) | Chukrasone B在制备治疗急性痛风药物中的应用 | |
CN104288160A (zh) | 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗急性痛风药物中的应用 | |
CN103381163B (zh) | Chukrasone A在制备治疗急性痛风药物中的应用 | |
CN103405426B (zh) | 一种化合物在制备治疗急性痛风药物中的应用 | |
CN103768049B (zh) | Eryngiolide A在治疗急性痛风药物中的应用 | |
CN103127087A (zh) | Aphanamixoid A在治疗急性痛风药物中的应用 | |
CN105456245A (zh) | Vulgarisin A在制备治疗急性痛风药物中的应用 | |
CN104825470A (zh) | 闭花木酮的o-(苯并咪唑基)乙基衍生物在制备抗急性痛风药物中的应用 | |
CN102988384A (zh) | Houttuynoid C在制备治疗急性痛风药物中的应用 | |
CN105412069A (zh) | Herqueioxazole在制备治疗急性痛风药物中的应用 | |
CN105078987A (zh) | 组合物38083001030527及其在抗急性痛风药物中的应用 | |
CN105343043A (zh) | 一种组合物及其在抗急性痛风药物中的应用 | |
CN103462950B (zh) | Scopariusins在制备治疗急性痛风药物中的应用 | |
CN105287451A (zh) | Foveoeudesmenone在制备治疗急性痛风药物中的应用 | |
CN105250991A (zh) | Geodiamolide A在制备治疗急性痛风药物中的应用 | |
CN102861030B (zh) | Gypensapogenin B在治疗急性痛风药物中的应用 | |
CN103356536A (zh) | Sarcaboside A在治疗急性痛风药物中的应用 | |
CN105250266A (zh) | Hirsutellone B在制备治疗急性痛风药物中的应用 | |
CN102861033B (zh) | Gypensapogenin A在治疗急性痛风药物中的应用 | |
CN103285007A (zh) | Myriberine A在制备治疗急性痛风药物中的应用 | |
CN103463001B (zh) | Neonectrolide A在制备治疗急性痛风药物中的应用 | |
CN105287579A (zh) | 组合物及其在抗急性痛风药物中的应用 | |
CN104873505A (zh) | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗急性痛风药物中的应用 | |
CN103655551B (zh) | Manzamenone O在制备治疗急性痛风药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: Tiefu iron rich street Pizhou city 221331 Jiangsu city of Xuzhou Province Patentee after: Ding Shengyu Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Patentee before: Ding Shengyu |
|
CP02 | Change in the address of a patent holder | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Lu Hongxian Inventor before: Ding Shengyu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171218 Address after: 535000 the Guangxi Zhuang Autonomous Region, Qinzhou, Qinnan District Building Street, No. 9 Patentee after: Qinzhou Industry Research Institute Address before: Tiefu iron rich street Pizhou city 221331 Jiangsu city of Xuzhou Province Patentee before: Ding Shengyu |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150916 Termination date: 20180704 |